TXMD · TherapeuticsMD, Inc. · Documents

May 15

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Revenue $416K ▼ 40.1% Net loss $3.6M Diluted EPS -$0.37

May 5

Current report 8-K Events of May 1

Entered into a material agreement

May 1

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2022

May 1

Proxy statement PRE 14A Meeting Jun 26, 2023

Proxy statement

Apr 21

Current report 8-K

Other events

Apr 7

Current report 8-K

Financial results, Regulation FD disclosure

Apr 7

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Revenue $69.96M ▲ 2619.1% Net income $112M Diluted EPS $11.96

Mar 31

Late filing notice NT 10-K

Late filing notice

Feb 27

Current report 8-K Events of Feb 21

Director or officer change, or executive pay

Jan 18

Current report 8-K Events of Jan 11

Director or officer change, or executive pay

Jan 12

Current report 8-K Events of Jan 6

Delisting notice or listing transfer

Jan 6

Current report 8-K/A Events of Dec 30

Director or officer change, or executive pay

Jan 3

Current report 8-K Events of Dec 30

Entered into a material agreement, Ended a material agreement, Completed an acquisition or sale of assets, Director or officer change, or executive pay, Regulation FD disclosure, Other events

Dec 5

Current report 8-K Events of Dec 4

Entered into a material agreement, Regulation FD disclosure

Dec 1

Current report 8-K Events of Nov 30

Entered into a material agreement

Nov 14

Current report 8-K

Financial results, Regulation FD disclosure

Nov 14

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Revenue $20.92M ▼ 17.7% Net loss $28.97M Diluted EPS -$3.13

Oct 31

Current report 8-K Events of Oct 28

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Oct 3

Current report 8-K Events of Sep 30

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Sep 12

Current report 8-K Events of Sep 6

Director or officer change, or executive pay, Regulation FD disclosure

Aug 29

Current report 8-K Events of Aug 23

Director or officer change, or executive pay

Aug 15

Earnings call

Q2 2022 earnings call

Aug 15

Current report 8-K

Financial results, Regulation FD disclosure

Aug 15

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Revenue $28.56M ▲ 24.2% Net income $112.28M Diluted EPS $12.39

Aug 1

Current report 8-K Events of Jul 29

Entered into a material agreement, Unregistered sale of equity, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Regulation FD disclosure

Jul 29

Current report 8-K Events of Jul 28

Entered into a material agreement

Jul 28

Current report 8-K Events of Jul 27

Entered into a material agreement

Jul 25

Current report 8-K Events of Jul 24

Entered into a material agreement, Other events

Jul 14

Current report 8-K Events of Jul 13

Entered into a material agreement, Ended a material agreement

Jul 13

Tender offer SC 14D9/A

Tender offer

Jul 13

Tender offer SC TO-T/A

Tender offer

Jul 6

Tender offer SC 14D9/A

Tender offer

Jul 6

Tender offer SC TO-T/A

Tender offer

Jun 28

Tender offer SC 14D9/A

Tender offer

Jun 23

Tender offer SC TO-T/A

Tender offer

Jun 13

Tender offer SC 14D9

Tender offer

Jun 6

Current report 8-K/A Events of May 27

Charter or bylaw amendment, or fiscal year change

Jun 6

Tender offer SC TO-T

Tender offer

Jun 3

Current report 8-K Events of May 27

Entered into a material agreement

May 31

Current report 8-K Events of May 27

Entered into a material agreement, Other events

May 31

Tender offer SC TO-C

Tender offer

May 20

Current report 8-K

Regulation FD disclosure, Other events

May 16

Earnings call

Q1 2022 earnings call

May 16

Current report 8-K

Financial results, Regulation FD disclosure

May 16

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Revenue $19.33M ▼ 2.7% Net loss $49.02M

May 9

Current report 8-K Events of May 3

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change

Apr 29

Annual report 10-K/A Ended Dec 31

Annual report for the period ended Dec 31, 2021

Apr 27

Current report 8-K

Other events

Apr 20

Current report 8-K Events of Apr 14

Completed an acquisition or sale of assets, Debt obligation accelerated or increased

Apr 14

Current report 8-K

Regulation FD disclosure